The future of melanoma therapy: developing new drugs and improving the use of old ones

Future Oncol. 2016 Nov;12(22):2531-2534. doi: 10.2217/fon-2015-0045. Epub 2016 Oct 7.
No abstract available

Keywords: MEK inhibitor; adjuvant treatment; adoptive cell therapy; biological therapy; checkpoint inhibitors; immunotherapy; ipilimumab; melanoma; target therapy BRAF inhibitor.

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Azetidines / therapeutic use
  • Chemotherapy, Adjuvant
  • Drug Discovery
  • Drug Therapy, Combination
  • Humans
  • Imidazoles / therapeutic use
  • Indoles / therapeutic use
  • Ipilimumab / therapeutic use
  • MAP Kinase Kinase 1 / antagonists & inhibitors
  • MAP Kinase Kinase 2 / antagonists & inhibitors
  • Melanoma / drug therapy*
  • Melanoma / secondary
  • Molecular Targeted Therapy
  • Neoplasm Metastasis
  • Nivolumab
  • Oximes / therapeutic use
  • Piperidines / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Pyridones / therapeutic use
  • Pyrimidinones / therapeutic use
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Sulfonamides / therapeutic use
  • Vemurafenib

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Azetidines
  • Imidazoles
  • Indoles
  • Ipilimumab
  • Oximes
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyridones
  • Pyrimidinones
  • Sulfonamides
  • Vemurafenib
  • Nivolumab
  • trametinib
  • atezolizumab
  • pembrolizumab
  • Proto-Oncogene Proteins B-raf
  • MAP Kinase Kinase 1
  • MAP Kinase Kinase 2
  • cobimetinib
  • dabrafenib